News | May 16, 2022
Biological E. reduces Corbevax price to Rs.250 a dose
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
In clinical trials, treatment proved more effective than other therapies evaluated
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
Boehringer Ingelheim continues to innovate to enhance the customer experience and improve animal health and well-being
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
The cloud platform will empower biotech companies and CROs with an integrated solution for clinical data management and is supported by Emmes specialist data management teams
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Subscribe To Our Newsletter & Stay Updated
